Literature DB >> 21686765

Lymphoedema: a paradoxical effect of tumour necrosis factor inhibitors - case report and review of literature.

Hajra Ismail Tily1, Andras Perl.   

Abstract

This report describes the development of lymphoedema in a patient with rheumatoid arthritis (RA) who was treated with tumour necrosis factor α (TNFα) inhibitors.The patient was a 62-year-old woman with a long-standing history of RA that had been uncontrolled with steroids and methotrexate. Eight months after initiation of treatment with TNFα inhibitors she developed progressive symmetrical ascending non-pitting oedema of both legs with extensive keratinisation. A diagnosis of lymphoedema was made based on the clinical presentation and exclusion of alternative diagnoses. Skin biopsy showed dermatosclerosis consistent with lymphoedema. The temporal relationship suggested a link between the initiation of TNFα inhibitors and the development of lymphoedema. TNFα inhibitors are widely used to treat inflammatory diseases including lymphoedema. Paradoxically, there are reports suggesting the appearance of psoriasis, vasculitis and other inflammatory cutaneous conditions after the use of TNFα inhibitors. A review of literature is also presented.

Entities:  

Year:  2009        PMID: 21686765      PMCID: PMC3027781          DOI: 10.1136/bcr.07.2008.0520

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  14 in total

1.  Beneficial effect of etanercept on rheumatoid lymphedema.

Authors:  B E Ostrov
Journal:  Arthritis Rheum       Date:  2001-01

2.  Therapy for severe necrotizing vasculitis with infliximab.

Authors:  Renz Mang; Thomas Ruzicka; Helger Stege
Journal:  J Am Acad Dermatol       Date:  2004-08       Impact factor: 11.527

Review 3.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

4.  Pathology of lymphedema.

Authors:  J Daróczy
Journal:  Clin Dermatol       Date:  1995 Sep-Oct       Impact factor: 3.541

5.  Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.

Authors:  H-H Lee; I-H Song; M Friedrich; A Gauliard; J Detert; J Röwert; H Audring; S Kary; G-R Burmester; W Sterry; M Worm
Journal:  Br J Dermatol       Date:  2007-03       Impact factor: 9.302

6.  Immunology of cutaneous vasculitis associated with both etanercept and infliximab.

Authors:  M D Srivastava; F Alexander; R J Tuthill
Journal:  Scand J Immunol       Date:  2005-04       Impact factor: 3.487

Review 7.  Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.

Authors:  Uwe Wollina; Gesina Hansel; André Koch; Jaqueline Schönlebe; Erich Köstler; Gunter Haroske
Journal:  Am J Clin Dermatol       Date:  2008       Impact factor: 7.403

8.  Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.

Authors:  Niveditha Mohan; Evelyne T Edwards; Thomas R Cupps; Nancy Slifman; Jong-Hoon Lee; Jeffrey N Siegel; M Miles Braun
Journal:  J Rheumatol       Date:  2004-10       Impact factor: 4.666

9.  B cell activation in rheumatoid arthritis patients under infliximab treatment.

Authors:  S De Miguel; J A Jover; C Vadillo; E Judez; E Loza; B Fernandez-Gutierrez
Journal:  Clin Exp Rheumatol       Date:  2003 Nov-Dec       Impact factor: 4.473

10.  Persistent periorbital and facial lymphedema associated with Group A beta-hemolytic streptococcal infection (erysipelas).

Authors:  Golden T Buckland; J Andrew Carlson; Dale R Meyer
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2007 Mar-Apr       Impact factor: 1.746

View more
  1 in total

1.  [Unilateral lymphedema of the upper limb in a rheumatoid arthritis].

Authors:  Salem Bouomrani; Hanène Nouma; Alaeddine Slama; Safouane Chebbi; Marwa Neffoussi; Afef Fara; Maher Beji
Journal:  Pan Afr Med J       Date:  2015-07-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.